Second Primary Malignancies in Patients With B-Cell Lymphomas Treated With Bruton's Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis. [PDF]
Ma C, Lu Y, Li J, Liu W, Liu J.
europepmc +1 more source
Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis. [PDF]
Lambe J, Fox RJ.
europepmc +1 more source
Targeting Bruton's Tyrosine Kinase (BTK) in Autoimmunity: Achievements, Opportunities and Challenges. [PDF]
Torke S, Dybowski S, Weber MS.
europepmc +1 more source
Two-step mechanism of Bruton's tyrosine kinase membrane recruitment and activation. [PDF]
McAllister RA +5 more
europepmc +1 more source
Targeting Bruton's Tyrosine Kinase in CLL: Selectivity, Resistance Mechanisms, and Emerging Therapeutic Strategies. [PDF]
Bravo E +4 more
europepmc +1 more source
Visualization of a Bruton's Tyrosine Kinase Inhibitor Using Fluorescence and Raman Microscopy. [PDF]
Merchant AS +3 more
europepmc +1 more source
First-Line Bruton's Tyrosine Kinase Inhibitor-Based Regimens for Mantle Cell Lymphoma. [PDF]
Puckrin R +4 more
europepmc +1 more source
Membrane-dependent assembly of Bruton's tyrosine kinase mediated by the Proline-rich region and SH3 domain. [PDF]
Fenton AD, Chung JK.
europepmc +1 more source
Evaluation of Cardiotoxicity in Lymphoproliferative Patients Treated With Anthracycline and Bruton's Tyrosine Kinase Inhibitor-Based Regimens. [PDF]
Bonsu A.
europepmc +1 more source
A Novel Bruton's Tyrosine Kinase Inhibitor Suppresses Pancreatic Neuroendocrine Neoplasms Progression via ATF3-Induced Ferroptosis. [PDF]
Hu P +10 more
europepmc +1 more source

